
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology.
The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an extensive scientific program. In a recent video for Urology Times®, Betty Wang, MD, provided insight on 3 presentations that she believes “may be game changing” in urology.






